Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,940,000 shares, a decrease of 6.7% from the January 15th total of 3,150,000 shares. Based on an average daily trading volume, of 708,000 shares, the days-to-cover ratio is presently 4.2 days.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Piper Sandler restated an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Barclays upped their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Finally, Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $299.48.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,356 shares of company stock worth $22,498,551 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Huntington National Bank grew its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 73 shares during the period. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth $29,000. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $33,000. Finally, OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $35,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 2.5 %

Shares of Alnylam Pharmaceuticals stock opened at $250.00 on Wednesday. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a market cap of $32.25 billion, a price-to-earnings ratio of -95.42 and a beta of 0.35. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company’s 50-day moving average price is $253.96 and its 200-day moving average price is $263.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts expect that Alnylam Pharmaceuticals will post -2.24 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.